US4512972A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Nasal preparation and processes for their production
Assignee: Kureha Corp
•
Filing: 1981-08-24
•
Granted: 1985-04-23
•
Expires: 2001-08-24
Abstract
Abstract The present invention relates to nasal preparations which contain, as active ingredient, one or more nitrogen-containing polysaccharides obtained from fungi, in particular the polysaccharide krestin, and which exert a prophylactic action lasting several days against infections caused by viruses of the respiratory tract, especially influenza A and B viruses, as well as vaccine nasal preparations which contain the above mentioned active ingredient together with viruses of the respiratory tract of at least one strain and which impart a long-term protective action on single administration. The invention is also concerned with the production and use of these nasal preparations.
Inventors
- 👤 Karl H. Schmidt-Ruppin
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 17:47
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/70; A61K31/715; A61K39/00; A61K39/12; A61K39/145; A61K9/00; A61K9/0012; A61K9/0043; A61K2039/54; A61K2039/541; A61K2039/543; A61K2039/555; A61K2039/55511; A61K2039/55583; C; C12; C12N; C12N2760/00; C12N2760/00011; C12N2760/16011; C12N2760/16111; C12N2760/16134
Claims Analysis
Total Claims: 9
Claim 1
Independent Claim
106 words
A method of preventing infections caused by influenza A and B viruses of the respiratory tract, without inhibiting the formation of hemagglutinative serum antibodies against the virus, and without inhibiting plaque formation, which comprises applying into each nostril, up to seven days prior to infection, a preparation containing a prophylactically effective amount of krestin in a conventional medicinal formulation in order to protect the subject in the antibody-free latency period against infection by the same virus, to bridge the latency period of vaccination against influenza simultaneously with or directly after vaccination, or to ensure protection in the antibody-free latency period without impairment of the antibody formation.
Claim 2
Independent Claim
106 words
A method of preventing infections caused by influenza A and B viruses of the respiratory tract, without inhibiting the formation of hemagglutinative serum antibodies against the virus, and without inhibiting plaque formation, which comprises applying into each nostril, up to seven days prior to infection, a preparation containing a prophylactically effective amount of krestin in a conventional medicinal formulation in order to protect the subject in the antibody-free latency period against infection by the same virus, to bridge the latency period of vaccination against influenza simultaneously with or directly after vaccination, or to ensure protection in the antibody-free latency period without impairment of the antibody formation.
Claim 3
Dependent Claim
36 words
The method of claim 1 wherein said preparation contains, as active ingredient, the nitrogen-containing polysaccharide krestin, in a prophylactically effective amount, in a conventional medicinal formulation for intranasal application selected from gels, ointments, and aqueous solutions.
Claim 4
Dependent Claim
18 words
The method of claim 1 wherein said preparation contains a pharmaceutically acceptable excipient of sodium timerfonate [sodium p-(ethylmercurithio)-benzenesulfonate].
Claim 5
Dependent Claim
13 words
The method of claim 1 wherein said preparation contains 0.2 to 4% krestin.
Claim 6
Dependent Claim
29 words
The method of claim 2 wherein said preparation contains 0.2 to 1% of krestin when said conventional medicinal formulation is an aqueous solution in the form of a spray.
Claim 7
Dependent Claim
28 words
The method of claim 2 wherein said preparation contains 1 to 2% of krestin when said conventional medicinal formulation is an aqueous solution in the form of drops.
Claim 8
Dependent Claim
49 words
A method of claim 1 wherein said preparation further comprises a virulent strain of said infectious virus of the respiratory tract in an amount not exceeding that which becomes non-infectious at room to body temperature as a result of the action of the amount of krestin in said preparation.
Claim 9
Dependent Claim
19 words
The method of claim 4 wherein said preparation further contains a pharmaceutically acceptable excipient of sodium timerfonate [sodium p-(ethylmercurithio)-benzenesulfonate].
References Cited (Backward Citations)
FR2081341A2
Cited
JPS488489U
Cited
JPS5136322A
Cited
FR2293214A1
Cited
DE2553971A1
Cited
FR2312261A1
Cited
DE2655844A1
Cited
GB1521168A
Cited
DE2813353A1
Cited
FR2385734A1
Cited
DE2816087A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1988-04-22 | 1988-10-22 | 1989-04-23 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1992-04-22 | 1992-10-22 | 1993-04-23 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1996-04-22 | 1996-10-22 | 1997-04-23 | $7700.00 | Window Closed / Lapsed |